SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Iovance’s lifileucel shows responses in 50% of eight patients with advanced sarcomas

The therapy showed responses in 50% of eight patients in a pilot study of advanced sarcomas.

IOVA

Related stories